124 related articles for article (PubMed ID: 2175287)
1. Urinary gonadotropin fragment, a new tumor marker. IV. Use in endometrial cancers and uterine mixed mullerian tumors.
Nam JH; Chambers JT; Schwartz PE; Cole LA
Gynecol Oncol; 1990 Dec; 39(3):352-7. PubMed ID: 2175287
[TBL] [Abstract][Full Text] [Related]
2. Urinary gonadotropin fragment, a new tumor marker. III. Use in cervical and vulvar cancers.
Nam JH; Chang KC; Chambers JT; Schwartz PE; Cole LA
Gynecol Oncol; 1990 Jul; 38(1):66-70. PubMed ID: 2354828
[TBL] [Abstract][Full Text] [Related]
3. Urinary gonadotropin fragment (UGF) measurements in the diagnosis and management of ovarian cancer.
Cole LA; Nam JH
Yale J Biol Med; 1989; 62(4):367-78. PubMed ID: 2596125
[TBL] [Abstract][Full Text] [Related]
4. Urinary gonadotropin fragments (UGF) in cancers of the female reproductive system. I. Sensitivity and specificity, comparison with other markers.
Cole LA; Schwartz PE; Wang YX
Gynecol Oncol; 1988 Sep; 31(1):82-90. PubMed ID: 3044936
[TBL] [Abstract][Full Text] [Related]
5. Urinary human chorionic gonadotropin free beta-subunit and beta-core fragment: a new marker of gynecological cancers.
Cole LA; Wang YX; Elliott M; Latif M; Chambers JT; Chambers SK; Schwartz PE
Cancer Res; 1988 Mar; 48(5):1356-60. PubMed ID: 3342414
[TBL] [Abstract][Full Text] [Related]
6. Urinary gonadotropin fragments (UGF) in cancers of the female reproductive system. II. Initial serial studies.
Wang YX; Schwartz PE; Chambers JT; Cole LA
Gynecol Oncol; 1988 Sep; 31(1):91-102. PubMed ID: 3410359
[TBL] [Abstract][Full Text] [Related]
7. Beta-core fragment (beta-core/UGF/UGP), a tumor marker: a 7-year report.
Cole LA; Tanaka A; Kim GS; Park SY; Koh MW; Schwartz PE; Chambers JT; Nam JH
Gynecol Oncol; 1996 Feb; 60(2):264-70. PubMed ID: 8631549
[TBL] [Abstract][Full Text] [Related]
8. Urinary gonadotropin fragment, a new tumor marker. I. Assay development and cancer specificity.
Nam JH; Cole LA; Chambers JT; Schwartz PE
Gynecol Oncol; 1990 Mar; 36(3):383-90. PubMed ID: 2318449
[TBL] [Abstract][Full Text] [Related]
9. Urinary gonadotropin fragment, a new tumor marker. II. Differentiating a benign from a malignant pelvic mass.
Cole LA; Nam JH; Chambers JT; Schwartz PE
Gynecol Oncol; 1990 Mar; 36(3):391-4. PubMed ID: 2318450
[TBL] [Abstract][Full Text] [Related]
10. Urinary gonadotropin fragment measurements in patients with lung and esophageal disease.
D'Agostino RS; Cole LA; Ponn RB; Stern H; Schwartz PE
J Surg Oncol; 1992 Mar; 49(3):147-50. PubMed ID: 1548888
[TBL] [Abstract][Full Text] [Related]
11. Urinary chorionic gonadotropin subunits and beta-core in nonpregnant women. A study of benign and malignant gynecologic disorders.
Neven P; Iles RK; Lee CL; Hudson CN; Shepherd JH; Chard T
Cancer; 1993 Jun; 71(12):4124-30. PubMed ID: 7685240
[TBL] [Abstract][Full Text] [Related]
12. [Urinary gonadotropin fragment measurement in the monitoring of trophoblastic disease].
Fu CY; Cole LA; Kardana A
Zhonghua Fu Chan Ke Za Zhi; 1994 Aug; 29(8):475-7, 510-1. PubMed ID: 7835119
[TBL] [Abstract][Full Text] [Related]
13. Endometrial carcinoma with trophoblastic differentiation. An aggressive form of uterine cancer.
Pesce C; Merino MJ; Chambers JT; Nogales F
Cancer; 1991 Oct; 68(8):1799-802. PubMed ID: 1717127
[TBL] [Abstract][Full Text] [Related]
14. Assessment of urinary beta-core fragment of human chorionic gonadotropin as a new tumor marker of lung cancer.
Yoshimura M; Nishimura R; Murotani A; Miyamoto Y; Nakagawa T; Hasegawa K; Koizumi T; Shii K; Baba S; Tsubota N
Cancer; 1994 Jun; 73(11):2745-52. PubMed ID: 7514953
[TBL] [Abstract][Full Text] [Related]
15. Mixed müllerian tumors of the uterus: a clinicopathologic study.
Dinh TV; Slavin RE; Bhagavan BS; Hannigan EV; Tiamson EM; Yandell RB
Obstet Gynecol; 1989 Sep; 74(3 Pt 1):388-92. PubMed ID: 2548134
[TBL] [Abstract][Full Text] [Related]
16. CA 125: a useful marker in endometrial carcinoma.
Duk JM; Aalders JG; Fleuren GJ; de Bruijn HW
Am J Obstet Gynecol; 1986 Nov; 155(5):1097-102. PubMed ID: 3465243
[TBL] [Abstract][Full Text] [Related]
17. Adenocarcinoma of the uterine cervix. Prognostic significance of pretreatment serum CA 125, squamous cell carcinoma antigen, and carcinoembryonic antigen levels in relation to clinical and histopathologic tumor characteristics.
Duk JM; De Bruijn HW; Groenier KH; Fleuren GJ; Aalders JG
Cancer; 1990 Apr; 65(8):1830-7. PubMed ID: 2317761
[TBL] [Abstract][Full Text] [Related]
18. CA 125, NB/70K, and lipid-associated sialic acid in monitoring uterine papillary serous carcinoma.
Tseng PC; Sprance HE; Carcangiu ML; Chambers JT; Schwartz PE
Obstet Gynecol; 1989 Sep; 74(3 Pt 1):384-7. PubMed ID: 2761916
[TBL] [Abstract][Full Text] [Related]
19. Urinary mesothelin provides greater sensitivity for early stage ovarian cancer than serum mesothelin, urinary hCG free beta subunit and urinary hCG beta core fragment.
Badgwell D; Lu Z; Cole L; Fritsche H; Atkinson EN; Somers E; Allard J; Moore RG; Lu KH; Bast RC
Gynecol Oncol; 2007 Sep; 106(3):490-7. PubMed ID: 17532030
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of peritoneal washings in patients with malignant mixed müllerian tumors of the uterus.
Geszler G; Szpak CA; Harris RE; Creasman WT; Barter JF; Johnston WW
Am J Obstet Gynecol; 1986 Jul; 155(1):83-9. PubMed ID: 3014883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
